Related Experiment Video
Updated: Dec 10, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Multidisciplinary, three-dimensional and individualized comprehensive treatment for severe/critical COVID-19
Insights
A multidisciplinary, individualized approach significantly reduces mortality in severe COVID-19 patients. This strategy involves close monitoring and timely interventions for better outcomes.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pulmonology
Background:
- Severe/critical COVID-19 cases have a high mortality rate (up to 61.5%), particularly in elderly patients with comorbidities.
- SARS-CoV-2 damages multiple organs, including lungs, liver, immune system, and vasculature, leading to decreased organ function and accelerated disease progression.
- Effective management requires accurate disease prediction and timely interventions to mitigate mortality.
Purpose of the Study:
- To evaluate the effectiveness of a multidisciplinary, three-dimensional, individualized management strategy for severe/critical COVID-19 patients.
- To reduce mortality rates and improve cure rates in this high-risk patient population.
Main Methods:
- Implementation of a "multidisciplinary three-dimensional management, individualized comprehensive plan" for severe/critical COVID-19 patients.
- Involvement of a multidisciplinary team (MDT) including critical care, infectious disease, respiratory, and other specialists.
- "Round-the-clock rounds management" for close observation, timely evaluation, and rapid intervention.
Main Results:
- The MDT treated 77 severe/critical COVID-19 cases (average age 63.8 years, 68.8% with comorbidities).
- The treatment resulted in a significantly lower mortality rate (2.6%) and shorter hospital stay (22 days) compared to literature.
- A high cure rate of 84.4% was observed among severe cases.
Conclusions:
- A multidisciplinary, three-dimensional, and individualized comprehensive treatment plan is effective in reducing mortality and improving cure rates for severe/critical COVID-19.
- This approach enables accurate disease progression prediction and timely interventions, crucial for managing high-risk patients.
- The strategy highlights the importance of integrated care involving various medical specialties for optimal COVID-19 patient outcomes.
Abstract:
Severe/critical cases account for 18-20% of all novel coronavirus disease 2019 (COVID-19) patients, but their mortality rate can be up to 61.5%. Furthermore, all deceased patients were severe/critical cases. The main reasons for the high mortality of severe/critical patients are advanced age (>60 years old) and combined underlying diseases. Elderly patients with comorbidities show decreased organ function and low compensation for damage such as hypoxia and inflammation, which accelerates disease progression. The lung is the main target organ attacked by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while immune organs, liver, blood vessels and other organs are damaged to varying degrees. Liver volume is increased, and mild active inflammation and focal necrosis are observed in the portal area. Virus particles have also been detected in liver cells. Therefore, multidisciplinary teams (MDTs) and individualized treatment plans, accurate prediction of disease progression and timely interventions are vital to effectively reduce mortality. Specifically, a "multidisciplinary three-dimensional management, individualized comprehensive plan" should be implemented. The treatment plan complies with three principles, namely, multidisciplinary management of patients, individualized diagnosis and treatment plans, and timely monitoring and intervention of disease. MDT members are mainly physicians from critical medicine, infection and respiratory disciplines, but also include cardiovascular, kidney, endocrine, digestion, nerve, nutrition, rehabilitation, psychology and specialty care. According to a patient's specific disease condition, an individualized diagnosis and treatment plan is formulated (one plan for one patient). While selecting individualized antiviral, anti-inflammatory and immunomodulatory treatment, we also strengthen nutritional support, psychological intervention, comprehensive rehabilitation and timely and full-course intervention to develop overall and special nursing plans. In response to the rapid progression of severe/critical patients, MDT members need to establish a three-dimensional management model with close observation and timely evaluation. The MDT should make rounds of the quarantine wards both morning and night, and of critical patient wards nightly, to implement "round-the-clock rounds management", to accurately predict disease progression, perform the quick intervention and prevent rapid deterioration of the patient. Our MDT has cumulatively treated 77 severe/critical COVID-19 cases, including 62 (80.5%) severe cases and 15 (19.5%) critical cases, with an average age of 63.8 years. Fifty-three (68.8%) cases presented with more than one underlying disease and 65 (84.4%) severe cases recovered from COVID-19. The average hospital stay of severe/critical cases was 22 days, and the mortality rate was 2.6%, both of which were significantly lower than the 30-40 days and 49.0-61.5%, respectively, reported in the literature. Therefore, a multidisciplinary, three-dimensional and individualized comprehensive treatment plan can effectively reduce the mortality rate of severe/critical COVID-19 and improve the cure rate.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-III
Acute Coronary Syndrome IV: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
